Showing 2461-2470 of 5771 results for "".
- Staar Surgical Announces Resolution of FDA Warning Letterhttps://modernod.com/news/staar-surgical-announces-resolution-of-fda-warning-letter/2480080/STAAR Surgical announced that it received a close-out letter from the FDA on June 19, 2018 lifting a Warning Letter dated May 21, 2014. “The lifting of the Warning Letter is the result of a comprehensive remediation program that not only addressed the issues raised by the FDA in the 2014 W
- Avedro Announces Enrollment of First Patient in Phase 3 Epi-On Corneal Cross-Linking Trialhttps://modernod.com/news/avedro-announces-enrollment-of-first-patient-in-phase-3-epi-on-corneal-cross-linking-trial/2480082/Avedro announced that it has begun enrolling patients in a pivotal phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on corneal collagen cross-linking procedure to treat patients with progres
- Optovue Announces Expanded FDA Clearance of Epithelial Thickness Mappinghttps://modernod.com/news/optovue-announces-expanded-fda-clearance-of-epithelial-thickness-mapping/2480088/Optovue announced an expanded FDA 510(k) clearance for non-contact, quantitative measurements of the epithelial and stromal layers of the cornea, termed epithelial thickness mapping (ETM). The expanded clearance adds a 9-millimeter ETM scan to the previously available 6-millimeter map, allowing f
- Clearside Biomedical Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of CLS-TA in RVOhttps://modernod.com/news/clearside-biomedical-announces-completion-of-patient-enrollment-in-first-of-two-phase-3-clinical-trials-of-cls-ta-in-retinal-vein-occlusion/2480092/Clearside Biomedical announced completion of patient enrollment in a phase 3 clinical trial of suprachoroidal CLS-TA used in combination with intravitreally administered Eylea (aflibercept) for the treatment of retinal vein occlusion (RVO). SAPPHIRE, a multi
- Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR Implanthttps://modernod.com/news/allergan-announces-positive-topline-phase-3-clinical-data-for-bimatoprost-sr-implant/2480095/Allergan announced the release of new topline clinical trial data on Bimatoprost SR, a sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Bim
- Coburn Technologies Announces New Location for Corporate Headquartershttps://modernod.com/news/coburn-technologies-announces-new-location-for-corporate-headquarters/2480113/Coburn Technologies announced the relocation of their corporate headquarters to a newly renovated, modern facility in South Windsor, Connecticut. Effective July 23, 2018, Coburn Technologies will operate from their new location – 83 Gerber Road West, South Windsor, Connecticut, 06074.
- Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticalshttps://modernod.com/news/nicox-announces-research-collaboration-on-novel-ophthalmic-therapeutics-with-ironwood-pharmaceuticals/2480117/Nicox SA announced its entry into a research collaboration with Ironwood Pharmaceuticals focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new
- Clearside Biomedical Announces Topline Results from Phase 2 Clinical Trial of DME Combination Drughttps://modernod.com/news/clearside-biomedical-announces-positive-topline-results-from-phase-2-clinical-trial-of-dme-combination-drug/2480130/Clearside Biomedical announced positive topline results from its phase 2 clinical trial evaluating suprachoroidal CLS-TA used with intravitreally administered Eylea (aflibercept) in patients with diabetic macular edema (DME) over a 6-month evaluation period, according to a company news release.</
- BioTime Announces $1.9 Million Grant for Continued Development of OpRegen for Dry-AMDhttps://modernod.com/news/biotime-announces-1-9-million-grant-for-continued-development-of-opregen-for-dry-amd/2480136/BioTime has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (IIA). The grant provides funding for the continued development of OpRegen, and to date the IIA has provided annual grants totaling over $13 mil
- Optovue Announces Retirement of Industry Veteran John Hawleyhttps://modernod.com/news/optovue-announces-retirement-of-industry-veteran-john-hawley/2480137/Optovue announced the retirement of renowned industry veteran John Hawley, the company’s senior vice president of global sales. Mr. Hawley will retire on July 1, 2018, and remain with Optovue in an advisory role. “For the past 10 years, I have worked side-by-side with John as we built Opto